α-Blocker Treatment Linked to Worse Cardiovascular Outcomes in Patients With Benign Prostatic Hyperplasia
These new findings are important as α-blockers (ABs) are the most prescribed class of medications for patients with benign prostatic hyperplasia (BPH), but the cardiovascular safety profile of this treatment is not well understood for this patient population.
Source: ajmc.com